TopMD measures the topological shape of gene expression relative to gene interaction maps. Personalised TopMD Maps of global pathway activity are plotted using standard global gene expression data (microarray, RNAseq, proteomics etc.). Pathway modulation is measured with unprecedented accuracy, without data reduction required for pathway analysis using standard pathway analysis tests of association.
TopMD Maps can be used as high confidence biomarkers. TopMD Maps reflect the patterns of relative abundance for thousands of genes relative to known interactions, delivering high confidence biomarkers. Discrete biomarkers, or panels of discrete biomarkers are subject to variability in technical measurement, cohorts and individuals. TopMD Maps accurately reflect global pathway modulation offering improved performance as biomarkers compared to discrete biomarkers.
TopMD is poised to streamline the way diseases are diagnosed. Using well understood and easily accessible gene expression technologies, TopMD offers a multi-disease diagnostic platform promoting affordability, ease-of-use, and faster results delivery.
Dysregulation of normal activity within biological pathways can result in disease. However, clinically discrete diseases often result from different aberrations of underlying biological pathways. Drugs are typically designed to restore a single biological pathway to normality, and their effectiveness is resultingly variable when applied to a cohort of patients with mixed sub-phenotypes.
TopMD Maps identify modulated pathways underpinning disease phenotypes bringing greatly improved accuracy compared to discrete biomarkers identified by differential gene expression analysis. Given gene expression data from a disease cohort, TopMD can stratify sub-phenotypes according to similarity in TopMD Maps, representing common pathway modulation associated with disease.
Drug response relies on clinical pathology resulting from modulation of pathways targeted by the drug. Prediction of the rate of drug response in a cohort can be calculated using TopMD Maps which accurately reflect global pathway modulation.
The risk of a drug trial failure can be reduced by recruiting the right disease cohort using TopMD Maps to identify modulations of pathways targeted by the drug.